[
  {
    "ts": null,
    "headline": "Is Edwards Lifesciences (EW) Share Weakness Creating A Valuation Opportunity?",
    "summary": "If you are wondering whether Edwards Lifesciences is attractively priced right now, it helps to first look past the headline share price and focus on what different valuation methods are saying. The stock recently closed at US$78.10, with a 7 day return of a 4.2% decline, a 30 day return of a 9.0% decline, and a year to date return of an 8.5% decline, while the 1 year return sits at 10.0%. Recent coverage around Edwards Lifesciences has focused on its role in the broader healthcare sector...",
    "url": "https://finnhub.io/api/news?id=6245bbcd69ff6e4019820a7bbd25caf31bed70a87ab93afb38eccad8a62d39f1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770386848,
      "headline": "Is Edwards Lifesciences (EW) Share Weakness Creating A Valuation Opportunity?",
      "id": 138375600,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "EW",
      "source": "Yahoo",
      "summary": "If you are wondering whether Edwards Lifesciences is attractively priced right now, it helps to first look past the headline share price and focus on what different valuation methods are saying. The stock recently closed at US$78.10, with a 7 day return of a 4.2% decline, a 30 day return of a 9.0% decline, and a year to date return of an 8.5% decline, while the 1 year return sits at 10.0%. Recent coverage around Edwards Lifesciences has focused on its role in the broader healthcare sector...",
      "url": "https://finnhub.io/api/news?id=6245bbcd69ff6e4019820a7bbd25caf31bed70a87ab93afb38eccad8a62d39f1"
    }
  },
  {
    "ts": null,
    "headline": "Estimating The Fair Value Of Edwards Lifesciences Corporation (NYSE:EW)",
    "summary": "Key Insights Edwards Lifesciences' estimated fair value is US$89.38 based on 2 Stage Free Cash Flow to Equity With...",
    "url": "https://finnhub.io/api/news?id=6f17eac3aaa0e8af8f86f92c067d917ba22ec5e41dc86d433c53faa52f484181",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770386446,
      "headline": "Estimating The Fair Value Of Edwards Lifesciences Corporation (NYSE:EW)",
      "id": 138375601,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "EW",
      "source": "Yahoo",
      "summary": "Key Insights Edwards Lifesciences' estimated fair value is US$89.38 based on 2 Stage Free Cash Flow to Equity With...",
      "url": "https://finnhub.io/api/news?id=6f17eac3aaa0e8af8f86f92c067d917ba22ec5e41dc86d433c53faa52f484181"
    }
  },
  {
    "ts": null,
    "headline": "The TAVR Pioneer Bets Everything on One Market as Its Competitor Spreads Risk",
    "summary": "Edwards Lifesciences (NYSE: EW) and Boston Scientific (NYSE: BSX) both reported strong quarters, but the results reveal fundamentally different strategies in the heart device market. Edwards doubled down on transcatheter valve replacement with $1.15 billion in TAVR sales, up 12.4%, while Boston Scientific exited TAVR entirely and leaned into its diversified cardiovascular platform. One Specialist, ... The TAVR Pioneer Bets Everything on One Market as Its Competitor Spreads Risk",
    "url": "https://finnhub.io/api/news?id=3507a3d67d7208b5f1044f8deac437c2f46c77ad4605acd398de7a75fc7b99c5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770383735,
      "headline": "The TAVR Pioneer Bets Everything on One Market as Its Competitor Spreads Risk",
      "id": 138375553,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "EW",
      "source": "Yahoo",
      "summary": "Edwards Lifesciences (NYSE: EW) and Boston Scientific (NYSE: BSX) both reported strong quarters, but the results reveal fundamentally different strategies in the heart device market. Edwards doubled down on transcatheter valve replacement with $1.15 billion in TAVR sales, up 12.4%, while Boston Scientific exited TAVR entirely and leaned into its diversified cardiovascular platform. One Specialist, ... The TAVR Pioneer Bets Everything on One Market as Its Competitor Spreads Risk",
      "url": "https://finnhub.io/api/news?id=3507a3d67d7208b5f1044f8deac437c2f46c77ad4605acd398de7a75fc7b99c5"
    }
  }
]